ZC3H15 is a zinc finger CCCH-type protein involved in multiple cellular processes with emerging roles in cancer and systemic disease. At the molecular level, ZC3H15 protects the GTPase DRG1 from degradation and stimulates its GTPase activity, likely through enhanced potassium ion affinity. Beyond this canonical function, ZC3H15 regulates protein stability through ubiquitin-mediated pathways: it recruits the E3 ligase TRIM56 to promote PTEN ubiquitination in non-small cell lung cancer cells 1, reduces EGFR ubiquitination to stabilize EGFR in glioblastoma 2, and maintains KEAP1 stability to promote NRF2 degradation under oxidative stress 3. ZC3H15 also interacts with telomerase and regulates its subcellular localization to modulate telomere length maintenance 4. Clinically, ZC3H15 is significantly overexpressed in pediatric acute myeloid leukemia 5, non-small cell lung cancer 1, hepatocellular carcinoma 6, glioblastoma 2, and melanoma 7, where elevated levels correlate with poor prognosis and advanced disease. In bone cancer pain, ZC3H15 suppression via AAV-delivered shRNA ameliorates nociceptive behaviors by reducing neuronal oxidative stress and microglial inflammation 3. Recent evidence suggests ZC3H15 is a potential therapeutic target in multiple malignancies, with suppression strategies warranting investigation as treatment approaches.